Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histiocytosis X.

M B Nolph, G A Luikin

    Otolaryngologic Clinics of North America
    |August 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Histiocytosis X, a disorder of mononuclear phagocytic cells, can resolve spontaneously or progress. Treatment and prognosis depend on disease extent, with conservative approaches for local cases and further research needed for systemic disease.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Surgical and nonsurgical complications associated with cochlear prosthesis implantation.

    The American journal of otology·1990
    Same author

    Epidermal growth factor binding and action on tympanic membranes.

    The Annals of otology, rhinology, and laryngology·1990
    Same author

    Deafness and cochlear implants. Results of clinical trials.

    The Journal of the Kentucky Medical Association·1987
    Same author

    Bone and cartilage in the repair of laryngotracheal stenosis.

    Ear, nose, & throat journal·1986
    Same author

    Hearing loss in childhood communication disorders.

    The Journal of the Kentucky Medical Association·1984
    Same author

    Raeder's syndrome associated with internal carotid artery dilation and sinusitis.

    The Laryngoscope·1982
    Same journal

    Obesity and Obstructive Sleep Apnea: Impact on Medical and Surgical Management.

    Otolaryngologic clinics of North America·2026
    Same journal

    Little Tube; Big Problems: Eustachian Tube Dysfunction.

    Otolaryngologic clinics of North America·2026
    Same journal

    Current State of Button Battery Ingestion Injuries.

    Otolaryngologic clinics of North America·2026
    Same journal

    Diagnostic Algorithm for Eustachian Tube Dysfunction and Indications for Balloon Dilation of the Eustachian Tube.

    Otolaryngologic clinics of North America·2026
    Same journal

    Patulous Eustachian Tube Dysfunction.

    Otolaryngologic clinics of North America·2026
    Same journal

    Revisiting Eustachian Tube Anatomy and Physiology.

    Otolaryngologic clinics of North America·2026
    See all related articles

    Area of Science:

    • Immunology
    • Oncology
    • Pathology

    Background:

    • Histiocytosis X is a rare disorder involving mononuclear phagocytic cells.
    • Clinical presentation ranges from isolated to generalized involvement.
    • Etiology remains unknown, with theories suggesting a reaction to local inciting agents.

    Purpose of the Study:

    • To outline the clinical spectrum and management principles of Histiocytosis X.
    • To emphasize the importance of disease staging for treatment decisions.
    • To highlight areas for future research in treatment modalities.

    Main Methods:

    • Review of clinical presentations and outcomes.
    • Analysis of treatment strategies based on disease extent.
    • Discussion of potential etiologies and future research directions.

    Related Experiment Videos

    Main Results:

    • Histiocytosis X exhibits variable clinical behavior, including spontaneous resolution and systemic progression.
    • Head and neck manifestations are common, suggesting potential local triggers.
    • Prognosis and treatment are contingent upon disease staging.

    Conclusions:

    • Conservative management is recommended for localized Histiocytosis X.
    • Low-dose radiation therapy is an option for specific lesions.
    • Further randomized trials are necessary to establish the role of chemotherapy and immunotherapy in disseminated or aggressive disease.